Breaking News Instant updates and real-time market news.

A

Agilent

$65.78

-0.14 (-0.21%)

, MRK

Merck

$65.13

-0.47 (-0.72%)

16:36
09/22/17
09/22
16:36
09/22/17
16:36

Agilent receives expanded FDA approval for the use of Dako PD-L1 IHC 22C3

Agilent Technologies announced its Dako PD-L1 IHC 22C3 pharmDx assay has an expanded label approved by the FDA, for use as an aid in identifying gastric or GEJ adenocarcinoma patients for treatment with Keytruda, an anti-PD-1 therapy manufactured by Merck (MRK). The expanded approvals for PD-L1 IHC 22C3 pharmDx and Keytruda means that these patients now have the possibility of receiving a targeted anti-PD-L1 immunotherapy. PD-L1 IHC 22C3 pharmDx was used to assess PD-L1 expression in patients treated with Keytruda in the KEYNOTE-059 trial. KEYNOTE-059 is a registrational, phase 2, global, multicenter, non-randomized, open-label multicohort trial investigating the use of Keytruda in patients with advanced gastric or GEJ adenocarcinoma.

A

Agilent

$65.78

-0.14 (-0.21%)

MRK

Merck

$65.13

-0.47 (-0.72%)

  • 22

    Sep

  • 26

    Sep

  • 08

    Nov

  • 30

    Nov

A Agilent
$65.78

-0.14 (-0.21%)

07/12/17
WELS
07/12/17
UPGRADE
WELS
Outperform
Agilent upgraded to Outperform from Market Perform at Wells Fargo
07/13/17
WELS
07/13/17
NO CHANGE
WELS
Wells Fargo adjusts ratings in Life Science Tools space
Wells Fargo analyst Tim Evans changed ratings in the Life Science Tools sector to reflect in order to prioritize the pharma end market. For a Tools company, the pharma end market is "less price sensitive, less competitive, and more receptive to product cycles," Evans tells investors in a research note. To reflect this thesis, the analyst upgraded both Mettler-Toledo (MTD) and Agilent (A) to Outperform from Market Perform. He raised his price target for Mettler to $660 from $510 and for Agilent to $67 from $60. The analyst also downgraded Bruker (BRKR) to Underperform from Market Perform with an unchanged price target of $25. His favorite name in the Life Science Tools portion of his universe is Waters (WAT).
07/13/17
07/13/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Snap (SNAP) upgraded to Buy from Hold at Stifel with analyst Scott Devitt saying Snap shares offer a "compelling risk/reward opportunity." 2. Progressive (PGR) upgraded to Strong Buy from Outperform at Raymond James with analyst Gregory Peters saying he believes Progressive will continue to grow net premiums written at a double digit pace through 2017 and is well positioned to benefit from emerging smartphone technology to monitor and price for distracting driving over the next 24 months. 3. Agilent (A) upgraded to Outperform from Market Perform at Wells Fargo. 4. Hain Celestial (HAIN) upgraded to Buy from Hold at Maxim with analyst Anthony Vendetti saying that its fiscal 2018 guidance implies a turnaround in its business while the company's reporting of its prior financials without any major restatements has removed an accounting overhang. 5. Fastenal (FAST) upgraded to Strong Buy from Outperform at Raymond James analyst Sam Darkatsh saying he thinks yesterday's selloff in Fastenal shares is entirely related to MSC Industrial's (MSM) gross margin commentary and is unwarranted. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/16/17
JPMS
08/16/17
NO CHANGE
Target $70
JPMS
Overweight
Agilent price target raised to $70 from $65 at JPMorgan
JPMorgan analyst Tycho Peterson raised his price target for Agilent Technologies to $70 saying the company reported "yet another strong quarter" driven by "robust" biopharma and chemical and energy growth. The analyst reiterates an Overweight rating on the shares.
MRK Merck
$65.13

-0.47 (-0.72%)

08/23/17
RAJA
08/23/17
NO CHANGE
Target $36
RAJA
Strong Buy
Paratek takeover speculation 'seems plausible,' says Raymond James
After Bloomberg reported that Paratek Pharmaceuticals (PRTK) is exploring its strategic options, including a possible sale, after receiving takeover interest, Raymond James analyst Laura Chico said she sees omadacycline as a promising asset and sees a takeout as "certainly one plausible outcome." While its "probably premature to think about a takeout price," Chico said that a possible price could arguably fall in the high-$40 to low-$50 range, adding that Merck (MRK), Pfizer (PFE) and Allergan (AGN) would all be potential buyers. She keeps a Strong Buy rating and $36 price target on Paratek shares.
09/11/17
STFL
09/11/17
NO CHANGE
Target $29
STFL
Buy
NewLink Genetics price target raised to $29 from $14 at Stifel
Stifel analyst Stephen Willey believes recently-updated melanoma data from both NewLink Genetics' (NLNK) phase 2 indoximod program and Incyte (INCY) and Merck's (MRK) ESMO presentation confirm IDO inhibitors are more-than-likely synergizing with PD-1 inhibition, adding that NewLink's drug appears to yield "slightly-better efficacy" in "slightly-healthier" patients. He increased his price target on NewLink to $29 from $14 to reflect favorable risk adjustments and higher melanoma sales estimates and keeps a Buy rating on the stock.
09/11/17
BMOC
09/11/17
NO CHANGE
BMOC
Incyte trial result 'assures commercial success,' says BMO Capital
BMO Capital analyst M. Ian Somaiya says the results of a trial of Incyte's (INCY) epacadostat, its selective IDO1 enzyme inhibitor, in combination with Merck's (MRK) Keytruda, in patients with advanced melanoma eliminates the risk of an upcoming Phase 3 trial of epacadostat and "assures its commercial success." The analyst adds, however, that "the bar continues to be raised for IO combinations," which may make it difficult for Incyte's stock to rise in the near-term. The analyst trimmed his price target on the shares to $163 from $172 to reflect the company's capital raise. But he keeps an Outperform rating on the stock.
09/18/17
JEFF
09/18/17
NO CHANGE
JEFF
AbbVie remains top global Pharma pick at Jefferies
Jefferies analyst Jeffrey Holford says AbbVie (ABBV) remains his top global pick in Pharmaceuticals, followed by Bayer (BAYRY). In the U.S., the analyst lists Zoetis (ZTS), Bristol-Myers Squibb (BMY) and Eli Lilly (LLY) as his top picks behind AbbVie. Merck (MRK) and Novo Nordisk (NVO) are the analyst's least preferred stocks. Holford cut his price target for Underperform-rated Merck to $52 from $55 and raised his price target for Buy-rated Zoetis to $77 from $74.

TODAY'S FREE FLY STORIES

CVRS

Corindus

$0.95

-0.0071 (-0.74%)

06:49
02/20/18
02/20
06:49
02/20/18
06:49
Hot Stocks
Corindus receives FDA 510(k) clearance for CorPath GRX System »

Corindus Vascular…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

SVXY

ProShares Short VIX Short-Term Futures

$12.69

-0.22 (-1.70%)

06:49
02/20/18
02/20
06:49
02/20/18
06:49
Technical Analysis
ProShares Short VIX Short-Term Futures: Pivot points, pivot low broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BWXT

BWX Technologies

$64.12

-0.19 (-0.30%)

06:49
02/20/18
02/20
06:49
02/20/18
06:49
Hot Stocks
BWX Technologies subsidary awarded contracts for C$30M »

BWX Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

WMT

Walmart

$104.78

1.55 (1.50%)

06:48
02/20/18
02/20
06:48
02/20/18
06:48
Hot Stocks
Breaking Hot Stocks news story on Walmart »

Walmart sees FY19 CapEx…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 28

    Feb

  • 07

    Mar

WMT

Walmart

$104.78

1.55 (1.50%)

06:48
02/20/18
02/20
06:48
02/20/18
06:48
Hot Stocks
Walmart says moving to annual guidance framework with quarterly updates »

Walmart also commented…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 28

    Feb

  • 07

    Mar

SLDB

Solid Biosciences

$24.93

-1.34 (-5.10%)

, SRPT

Sarepta

$64.00

0.86 (1.36%)

06:48
02/20/18
02/20
06:48
02/20/18
06:48
Initiation
Solid Biosciences, Sarepta initiated  »

Solid Biosciences…

SLDB

Solid Biosciences

$24.93

-1.34 (-5.10%)

SRPT

Sarepta

$64.00

0.86 (1.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

USO

United States Oil Fund

$12.38

0.05 (0.41%)

06:47
02/20/18
02/20
06:47
02/20/18
06:47
Technical Analysis
United States Oil Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TVPT

Travelport

$13.22

0.14 (1.07%)

06:47
02/20/18
02/20
06:47
02/20/18
06:47
Earnings
Travelport reports Q4 adj. EPS 35c, consensus 23c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 26

    Feb

  • 30

    May

WMT

Walmart

$104.78

1.55 (1.50%)

06:47
02/20/18
02/20
06:47
02/20/18
06:47
Earnings
Walmart sees FY19 net sales growth 1.5%-2%, consensus $511.94B »

Sees FY19 effective tax…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 28

    Feb

  • 07

    Mar

CDXC

ChromaDex

$5.39

0.01 (0.19%)

06:47
02/20/18
02/20
06:47
02/20/18
06:47
Hot Stocks
ChromaDex announces two new collaborative human clinical studies on NIAGEN »

ChromaDex announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Mar

XOP

SPDR Oil Exploration and Production Fund

$33.92

-0.17 (-0.50%)

06:47
02/20/18
02/20
06:47
02/20/18
06:47
Technical Analysis
SPDR Oil Exploration and Production Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDT

Medtronic

$83.31

0.37 (0.45%)

06:47
02/20/18
02/20
06:47
02/20/18
06:47
Earnings
Medtronic backs FY18 adjusted EPS growth view of 9%-10%, consensus $4.77 »

In fiscal year 2018, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 14

    Mar

  • 23

    Mar

DGAZ

VelocityShares 3x Inv Natural Gas ETN

$31.88

0.71 (2.28%)

06:46
02/20/18
02/20
06:46
02/20/18
06:46
Technical Analysis
VelocityShares 3x Inv Natural Gas ETN: Pivot points, pivot low broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGS

PlayAGS

$19.95

0.11 (0.55%)

06:46
02/20/18
02/20
06:46
02/20/18
06:46
Initiation
PlayAGS initiated  »

PlayAGS initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLRD

Tailored Brands

$23.31

-0.01 (-0.04%)

06:45
02/20/18
02/20
06:45
02/20/18
06:45
Hot Stocks
Tailored Brands launches three week custom delivery »

Men's Wearhouse and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Mar

TFX

Teleflex

$267.89

2.28 (0.86%)

06:45
02/20/18
02/20
06:45
02/20/18
06:45
Hot Stocks
Teleflex subsidiary announces FDA cleared new indication for UroLift »

NeoTract, a wholly owned…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 28

    Feb

  • 01

    Mar

  • 14

    Mar

ADM

Archer Daniels

$43.13

0.265 (0.62%)

, SYT

Syngenta

06:45
02/20/18
02/20
06:45
02/20/18
06:45
Periodicals
ADM, Syngenta settle lawsuit over biotech corn exports to China, Reuters reports »

Archer Daniels Midland…

ADM

Archer Daniels

$43.13

0.265 (0.62%)

SYT

Syngenta

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDT

Medtronic

$83.31

0.37 (0.45%)

06:45
02/20/18
02/20
06:45
02/20/18
06:45
Earnings
Medtronic reports Q3 adjusted EPS $1.17, consensus $1.17 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 14

    Mar

  • 23

    Mar

UGAZ

VelocityShares 3x Long Natural Gas ETN

$52.20

-1.3 (-2.43%)

06:45
02/20/18
02/20
06:45
02/20/18
06:45
Technical Analysis
VelocityShares 3x Long Natural Gas ETN: Pivot points, pivot high broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAGS

PagSeguro Digital

$30.36

1.28 (4.40%)

06:45
02/20/18
02/20
06:45
02/20/18
06:45
Initiation
PagSeguro Digital initiated  »

PagSeguro Digital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AERI

Aerie Pharmaceuticals

$54.90

1.25 (2.33%)

, EGRX

Eagle Pharmaceuticals

$64.78

-0.07 (-0.11%)

06:44
02/20/18
02/20
06:44
02/20/18
06:44
Hot Stocks
Aerie Pharmaceuticals appoints John LaRocca as General Counsel »

Aerie Pharmaceuticals…

AERI

Aerie Pharmaceuticals

$54.90

1.25 (2.33%)

EGRX

Eagle Pharmaceuticals

$64.78

-0.07 (-0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 26

    Feb

  • 28

    Feb

  • 05

    Apr

EWZ

MSCI Brazil Index

$45.54

0.03 (0.07%)

06:43
02/20/18
02/20
06:43
02/20/18
06:43
Technical Analysis
MSCI Brazil Index: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NCMGY

Newcrest Mining

$17.47

-0.87 (-4.74%)

06:43
02/20/18
02/20
06:43
02/20/18
06:43
Upgrade
Newcrest Mining rating change  »

Newcrest Mining upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EFA

iShares MSCI EAFE Index Fund

$71.42

0.32 (0.45%)

06:43
02/20/18
02/20
06:43
02/20/18
06:43
Technical Analysis
iShares MSCI EAFE Index Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNK

SPDR Barclays High Yield Bond

$36.32

0.18 (0.50%)

06:42
02/20/18
02/20
06:42
02/20/18
06:42
Technical Analysis
SPDR Barclays High Yield Bond: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.